-
Argenx statement to the ALS community
February 27, 2026 Update on adimanebart Phase 2a reALISe study in people living with ALS Today, argenx shares an important update on the adimanebart Phase 2a reALISe study in people… More >>
-
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with ALS
February 9, 2026 VTx-002 is a first-in-class vectorized antibody to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review VectorY Therapeutics, a leader in… More >>
-
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase… More >>
-
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Therapeutics, a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational… More >>
-
Collaborative Partnership between IQVIA and TRICALS
Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s Disease (LGD) in the US, is a progressive neurodegenerative disease. Although relatively rare, with 2 new… More >>
-
IONIS ALS community statement on completion of enrollment of FUSION clinical trial of ulefnersen
Dear ALS/MND Community, We are writing to inform you that Ionis has completed enrollment of FUSION (NCT04768972), the pivotal Phase 3 clinical trial of our investigational medicine, ulefnersen (ION363). FUSION… More >>
-
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
• DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo • DAZALS met… More >>
-
Results MIROCALS clinical trial with low-dose IL-2 in ALS – The Lancet
Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves… More >>
